Company Filing History:
Years Active: 1998
Title: Innovations in Cancer Risk Assessment by Jian Yu Rao
Introduction
Jian Yu Rao is an accomplished inventor based in Edmond, OK (US). He has made significant contributions to the field of cancer diagnostics through his innovative methods and systems. With a total of 2 patents, Rao's work focuses on enhancing the accuracy of cancer risk assessment, particularly for bladder cancer.
Latest Patents
Rao's latest patents include a groundbreaking cell analysis method that utilizes quantitative fluorescence image analysis. This system is designed to evaluate one or more biochemical markers for assessing individual cancer risk, diagnosing cancer, and monitoring therapeutic effectiveness and recurrence. The method involves automated quantitative fluorescence image analysis of cell samples collected from body organs. Cells are treated with a fixative solution that inhibits crystal formation, and the images of these cells are stored as grey level images for further analysis. A novel autofluorescence correction method is employed to enhance image quality. Additionally, a neural net computer is utilized to distinguish true-positive images from false-positive images, thereby improving the accuracy of cancer risk assessments. Cells with images positive for a marker can be compared to threshold quantities related to predetermined cancer risk.
Career Highlights
Jian Yu Rao is affiliated with the University of Oklahoma, where he continues to advance research in cancer diagnostics. His innovative approaches have garnered attention in the scientific community, contributing to the development of more effective cancer screening methods.
Collaborations
Some of his notable coworkers include George P Hemstreet, III and Robert E Hurst, who have collaborated with Rao on various research projects.
Conclusion
Jian Yu Rao's contributions to cancer diagnostics through his innovative patents highlight the importance of research in improving healthcare outcomes. His work exemplifies the potential of technology in transforming cancer risk assessment and diagnosis.